Market Overview

'$BCLI NurOwn for ALS. In the phase 2, there was no difference from placebo on ALSFRS scale. In fact, by 12 weeks follow-up, placebo patients were progressing slower. But sure, make a profit on RTT patients.' - -tweet from STAT News' Adam F

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Posted-In: Biotech News FDA General

 

Related Articles (BCLI)

Stifel: Nike 'Uniquely Positioned' In Shift To Direct-To-Consumer

Buy The Dip In Oracle? The Street Debates